Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | AGXT | P21549 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HRAS | P01112 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL538293 | 0.79 | TSHR (0.57) | TSHRNPC1RAB9AIDO1AGXT | |
| Hydrochloric Acid SCHEMBL11220071 | 0.77 | TSHR (0.55) | TSHRNPC1RAB9AIDO1AGXT | |
| SCHEMBL10106924 | 0.76 | IDO1 (0.52) | IDO1AGXTALDH1A1LMNA | |
| SCHEMBL8863647 | 0.75 | IDO1 (0.54) | TSHRNPC1RAB9AIDO1AGXT | |
| SCHEMBL4744780 | 0.75 | TSHR (0.52) | TSHRNPC1RAB9AIDO1AGXT | |
| SCHEMBL28510963 | 0.75 | TSHR (0.52) | TSHRNPC1RAB9AIDO1AGXT | |
| SCHEMBL4695833 | 0.75 | NPC1 (0.53) | TSHRNPC1RAB9AIDO1AGXT | |
| SCHEMBL10107046 | 0.74 | IDO1 (0.58) | RAB9AIDO1ALDH1A1 | |
| SCHEMBL10106851 | 0.74 | IDO1 (0.58) | IDO1AGXTLMNA | |
| Hydrochloric Acid SCHEMBL6477571 | 0.73 | MAPT (0.50) | TSHRNPC1RAB9AIDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108373442-B | Method for recovering abamectin intermediate isomer | 台州职业技术学院 | 2020-07-03 | — | — | CN | claimed |
| CN-116744793-B | Acarid-repellent composition and acarid-repellent product | 大日本除虫菊株式会社 | 2026-02-27 | — | — | CN | disclosed |
| CN-120152730-A | Recombinant IL-12 albumin binding domain fusion proteins for use in methods of treating cancer | 索尼特生物治疗公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-118510546-A | Treatment of primary cholangitis (PBC) with tolerogenic nanoparticles | 库尔制药开发公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118369345-A | Bispecific antibodies targeting CD137 and their use for anticancer immunotherapy | 圆祥生技股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118201961-A | PD-L1 targeted fusion proteins and methods of use thereof | GT生物制药公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117835999-A | Methods and means for enhancing therapeutic antibodies | 维肯芬特有限责任公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117729943-A | Iron (III) macrocyclic complexes with mixed hydroxyl side groups as MRI contrast agents | 纽约州立大学研究基金会 | 2024-03-19 | — | — | CN | disclosed |
| CN-117396607-A | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof | 阿劳诺斯治疗公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-117120084-A | Methods and means for modulating B cell mediated immune responses | 维肯芬特有限责任公司 | 2023-11-24 | — | — | CN | disclosed |
| US-7329679-B2 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7115645-B2 | 1,2 diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-03 | — | — | US | disclosed |
| US-20060205803-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20060094770-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| US-20020006948-A1 | 1,2 diarylbenzimdazoles and their pharmaceutical use | SCHERING AG | 2002-01-17 | — | — | US | disclosed |
| EP-0126088-A1 | ARYL SUBSTITUTED 7-OXABICYCLOHEPTANE COMPOUNDS | E.R. SQUIBB & SONS, INC. (US) | 1984-11-28 | — | — | EP | disclosed |
| US-4463015-A | Aryl substituted 7-oxabicycloheptane compounds, useful in inhibiting platelet aggregation | E. R. SQUIBB & SONS, INC. (US) | 1984-07-31 | — | — | US | disclosed |
| WO-1984000754-A1 | ARYL SUBSTITUTED 7-OXABICYCLOHEPTANE COMPOUNDS | SQUIBB & SONS INC (US) | 1984-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006948-A1 | 1,2 diarylbenzimdazoles and their pharmaceutical use | CYP2E1, CYP1B1, CYP1A1 | TSHR 4150/4885NPC1 961/4885RAB9A 2686/4885 |
| US-20060094770-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | ATP6V1B2, IL1B, GMFG | TSHR 4434/4885NPC1 1216/4885RAB9A 2600/4885 |
| US-20060205803-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | ATP6V1B2, IL1B, GMFG | TSHR 4434/4885NPC1 1216/4885RAB9A 2600/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | TSHR 4659/4885NPC1 2374/4885RAB9A 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.